Telix Pharmaceuticals
Company
telixpharma.com/Melbourne, AustraliaAbout
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) and Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) have been approved by the United States Food and Drug Administration (FDA)3, and Illuccix is approved in multiple jurisdictions globally.
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
Application Domain
Core Business
Technology
Therapeutic Area
Representatives
Telix EMEA Radioisotopes Strategy Director
Telix Pharmaceuticals